Stock AnalizHalozyme Therapeutics (HALO) earnings for the quarter ended September 2026: EPS beats estimates
Halozyme Therapeutics reported results for the quarter ended September 2026 on November 5, 2026. Adjusted earnings per share came in at $2.39 against the analysts’ average forecast of $2.36, a beat of 1.5%.
Revenue for the quarter was $493 million, up 39.2% from $354 million in the same quarter a year earlier.
The market’s verdict: the stock fell 20.5% on the first trading day after the report.
The last four quarters
Halozyme Therapeutics has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.39 | $2.36 | +1.5% | +39% | −20.5% |
| Jun 2026 | $2.28 | $1.82 | +25.5% | +48% | +23.4% |
| Mar 2026 | $1.60 | $1.52 | +5.3% | +42% | +10.6% |
| Sep 2025 | $1.72 | $1.63 | +5.5% | +22% | +4.4% |
What comes next
Analysts expect EPS of $2.63 for the next quarter on average and $8.89 for the fiscal year ending December 31, 2026.
The average analyst price target is $119.89, 20% above the current price of $100.27.
Valuation and score
Halozyme Therapeutics scores 3.4 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 25.0, and its intrinsic value under moderate assumptions is about 199% above the current market value. Full Halozyme Therapeutics analysis with 10 years of financials
Frequently asked questions
What was Halozyme Therapeutics’s EPS for the quarter ended September 2026?
$2.39 adjusted per share, against an analyst consensus of $2.36.
How much revenue did Halozyme Therapeutics report?
$493 million, up 39.2% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.